Research programme: iPSC-derived allogeneic cell therapies - Bristol Myers Squibb/ Century Therapeutics
Alternative Names: allogenic induced pluripotent cell therapies - Century Therapuetics/ Bristol Myers Squibb; iPSC derived allogenic immune cell therapies - Century Therapuetics/ Bristol Myers SquibbLatest Information Update: 19 Oct 2022
At a glance
- Originator Century Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; NKT cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Acute myeloid leukaemia; Multiple myeloma
Most Recent Events
- 19 Oct 2022 Century Therapeutics announces intention to submit IND for Hematological malignanciesin 2023 (Century Therapeutics pipeline, October 2022)
- 10 Jan 2022 Early research in Multiple myeloma in USA (Parenteral)
- 10 Jan 2022 Century Therapeutics and Bristol Myers Squibb agree to co-promote and co-develop iPSC-derived allogeneic sell therapies for Haematological malignancies